Isolation and cellular properties of mesenchymal cells derived from the decidua of human term placenta

Kanematsu, Daisuke; Shofuda, Tomoko; Yamamoto, Akira; Ban, Chiaki; Ueda, Takafumi; Yamasaki, Mami; Kanemura, Yonehiro

doi:10.1016/j.diff.2011.05.010

Cited by 48 publications

(40 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, pMSC express the Twist2 protein at lower levels compared to bmMSC and about 50% of pMSC lack expression of the Runx2 protein, central factors needed for efficient osteogenesis. In agreement with our results, an elevated mRNA expression of Twist2 was reported in human decidua-derived pMSC [18]. A possible explanation for these seemingly conflicting results may be the modification of translation of Twist2 encoding mRNA by small RNA species [56].…”

Section: Figsupporting

confidence: 89%

“…The rather low osteogenic potential of pMSC in comparison to bmMSC has been reported [18], and was associated at least, in part, with the differences in expression of ALP [10]. As ALP is the key enzyme utilized in the standard von Kossa staining method to detect mineralization of the matrix by osteoblasts, the prominent von Kossa staining generated from bmMSC could simply represent the differences in expression of ALP in bmMSC compared to pMSC.…”

Section: Discussionmentioning

confidence: 96%

“…For atMSC and pMSC, osteogenic differentiation was described [2,14,37,38]. However, recent studies reported a rather weak osteogenic differentiation of pMSC [10,18]. These seemingly conflicting results regarding the differentiation capacities of pMSC could be explained at least, in part, by different protocols for isolation and expansion of the cells.…”

Section: Discussionmentioning

confidence: 99%

“…MSC from another source, the synovial membrane, had a distinct chondrogenic potential [15], but failed to generate a stable cartilage ectopically [16]. Thus, in addition to the differences between the subsets of bmMSC enriched by monoclonal antibodies and FACS [12], MSC from other sources such as placenta or adipose tissue may differ in their gene expression patterns or in their regenerative potential as well [17,18].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Low Osteogenic Differentiation Potential of Placenta-Derived Mesenchymal Stromal Cells Correlates with Low Expression of the Transcription Factors Runx2 and Twist2

Ulrich

Rolauffs²,

Abele

et al. 2013

Stem Cells and Development

View full text Add to dashboard Cite

Recent studies indicated that mesenchymal stromal cells from bone marrow (bmMSC) differ in their osteogenic differentiation capacity compared to MSC from term placenta (pMSC). We extended these studies and investigated the expression of factors involved in regulation of bone metabolism in both cell types. To this end, MSC were expanded in vitro and characterized. The total transcriptome was investigated by microarrays, and for selected genes, the differences in gene expression were explored by quantitative reverse transcriptasepolymerase chain reaction, immunocytochemistry, and flow cytometry. We report that bmMSC and pMSC share expression of typical lineage surface markers, including CD73, CD90, CD105, and lack of CD14, CD34, and CD45. However, according to transcriptome analyses, they differ significantly in their expression of more than 590 genes. Factors involved in bone metabolism, including alkaline phosphatase (P < 0.05), osteoglycin (P < 0.05), osteomodulin (P < 0.05), runt-related transcription factor 2 (Runx2) (P < 0.04), and WISP2 (P < 0.05), were expressed at significantly lower levels in pMSC, but twist-related protein 2 (Twist2) (P < 0.0002) was expressed at significantly higher levels. The osteogenic differentiation capacity of pMSC was very low. The adipogenic differentiation was somewhat more prominent in bmMSC, while the chondrogenic differentiation seemed not to differ between bmMSC and pMSC, as determined by histochemical staining. However, expression and induction of peroxisome proliferator-activated receptor gamma-2 (PPARg2) and Sox9, factors involved in early adipogenesis and chondrogenesis, respectively, were higher in bmMSC. We conclude that despite many similarities between bmMSC and pMSC, when expanded under identical conditions, they vary considerably with respect to their in vitro differentiation potential. For regenerative purposes, the choice of MSC may therefore influence the outcome of a treatment considerably.

show abstract

Section: Figsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Low Osteogenic Differentiation Potential of Placenta-Derived Mesenchymal Stromal Cells Correlates with Low Expression of the Transcription Factors Runx2 and Twist2

Ulrich

Rolauffs²,

Abele

et al. 2013

Stem Cells and Development

View full text Add to dashboard Cite

show abstract

“…Recent work by Kanematsu and co-workers showed that human decidua MSC did express several enzymes of the MMP family [105].…”

Section: Interaction With An Inflammatory Context and Immune Modulatimentioning

confidence: 99%

Novel Immunomodulatory Markers Expressed by Human WJ-MSC: an Updated Review in Regenerative and Reparative Medicine

Rocca¹,

Corrao

Iacono

et al. 2012

TOTERMJ

View full text Add to dashboard Cite

Mesenchymal (stromal) stem cells (MSC) are a broad class of stromal populations which are able to differentiate towards mature cell types, and do express molecules involved in immune modulation, tolerance induction and inflammation dampening. MSC can be virtually isolated from each adult organ, as well as from foetus-associated perinatal tissues. In particular, Wharton's jelly-derived MSC (WJ-MSC) bear all of these key properties, together with their ease of sourcing and lack of ethical issues.Cellular therapy is a key technique in regenerative medicine approaches, in particular for the treatment of diseases in which physiological processes of cellular repopulation are blocked by the underlying pathological conditions. Recent data enlightened the ability of administered cells to act also in a repopulation-independent fashion in target organs, since their peculiar immunomodulatory and anti-inflammatory features may favor organ self-repair by reactivating local progenitors by both cell-mediated or paracrine mechanisms. Translating classical regenerative medicine to "reparative medicine" or "support medicine" should represent a further therapeutic strategy independent from the differentiation capacity of MSC populations.Recent data further highlighted that WJ-MSC outperform BM-MSC (which are now being applied clinically) both in terms of immune modulation and lack of tumorigenesis (or tumor-promoting activities) in vivo. Starting from these premises, this paper analyzes the recent data on the biology of WJ-MSC, considering the role of both naïve and differentiated cells in immune modulation. In particular, the role of tolerance promoting pathways via non-classical B7 costimulators or class Ib MHC molecules are examined. In addition, we also analyzed the interconnections with other mechanicistic pathways (as those driven by matrix degrading metalloproteinases) in immune modulation. Our observations strongly support the notion that WJ-MSC may constitute a new tool in regenerative and reparative medicine applications.

show abstract

Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

et al. 2013

View full text Add to dashboard Cite

The placenta protects the fetus from the mother's immune system. We have previously found that fetal membrane cells (FMCs) isolated from term placenta prevent alloreactivity in vitro. FMCs share many features with bone marrow‐derived mesenchymal stromal cells (MSCs), which we previously introduced to treat severe acute graft‐versus‐host disease (GVHD). Here, we tested FMCs for treatment of steroid‐refractory acute GVHD. After two passages in culture, approximately 109 FMCs were obtained from one single placenta, although not all cells from passage 0 and passage 1 were used for expansion. The FMCs were positive for CD29, CD44, CD73, CD90, CD105, and CD49d but were negative for hematopoietic, endothelial, and epithelial markers. Microsatellite polymorphism analysis showed that FMCs were of maternal origin. All FMCs used showed normal karyotype. Nine patients who had undergone hematopoietic stem cell transplantation (HSCT) and who had developed steroid‐refractory grade III–IV acute GVHD were given 0.9–2.8 × 106 FMCs per kg at 15 infusions. Median age was 57 years. There was no toxicity from infusion of FMCs in eight patients. One patient had seizures after infusion. Two of eight evaluable patients had a complete response and four had a partial response, giving an overall response rate of 75%. Two patients showed no response at all. Three patients are alive from 6 to 21 months after HSCT. One patient is well and two have chronic GVHD. Thus, FMCs may be successfully used for immune modulation and tissue repair. STEM CELLS2013;31:592–601

show abstract

Isolation and cellular properties of mesenchymal cells derived from the decidua of human term placenta

Cited by 48 publications

References 44 publications

Low Osteogenic Differentiation Potential of Placenta-Derived Mesenchymal Stromal Cells Correlates with Low Expression of the Transcription Factors Runx2 and Twist2

Low Osteogenic Differentiation Potential of Placenta-Derived Mesenchymal Stromal Cells Correlates with Low Expression of the Transcription Factors Runx2 and Twist2

Novel Immunomodulatory Markers Expressed by Human WJ-MSC: an Updated Review in Regenerative and Reparative Medicine

Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Contact Info

Product

Resources

About